Truist Securities Initiates Coverage On Legend Biotech with Buy Rating, Announces Price Target of $88
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has initiated coverage on Legend Biotech with a Buy rating and set a price target of $88.
June 17, 2024 | 10:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has initiated coverage on Legend Biotech with a Buy rating and set a price target of $88.
The initiation of coverage with a Buy rating and a price target of $88 by Truist Securities is likely to positively impact Legend Biotech's stock price in the short term as it reflects confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100